{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:16:15Z","timestamp":1785402975276,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2024.12.018","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T16:34:52Z","timestamp":1734798892000},"page":"422-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Karwatowska-Prokopczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Dibble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2024.12.018_bib0001","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.12.018_bib0002","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","article-title":"Clinical and biochemical features of different molecular etiologies of familial chylomicronemia","volume":"12","author":"Hegele","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0003","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12944-020-01302-x","article-title":"The burden of familial chylomicronemia syndrome in Canadian patients","volume":"19","author":"Gaudet","year":"2020","journal-title":"Lipids Health Disease"},{"key":"10.1016\/j.jacl.2024.12.018_bib0004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2024.12.018_bib0005","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","author":"Hegele","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0006","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.12.018_bib0007","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.12.018_bib0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/eurheartj\/ehab890","article-title":"Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?","volume":"43","author":"Hegele","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2024.12.018_bib0009","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.122.317966","article-title":"Broadening the scope of dyslipidemia therapy by targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)","volume":"43","author":"Ginsberg","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0010","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","author":"Watts","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2024.12.018_bib0011","doi-asserted-by":"crossref","first-page":"e99721","DOI":"10.1371\/journal.pone.0096482","article-title":"Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects","volume":"9","author":"Di Filippo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2024.12.018_bib0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MOL.0000000000000163","article-title":"Targeted next-generation sequencing in monogenic dyslipidemias","volume":"26","author":"Hegele","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0013","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2024.12.018_bib0014","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance","volume":"119","author":"Packard","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2024.12.018_bib0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","article-title":"Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results","volume":"57","author":"Yang","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2024.12.018_bib0016","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2024.12.018_bib0017","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","author":"Spagnuolo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2024.12.018_bib0018","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0019","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0020","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2024.12.018_bib0021","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","article-title":"Overproduction of large VLDL particles is driven by increased liver fat content in man","volume":"49","author":"Adiels","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2024.12.018_bib0022","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1161\/ATVBAHA.119.313051","article-title":"Functional Analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity","volume":"39","author":"Banerjee","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0023","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0022-2275(20)41752-3","article-title":"A stable, radioactive substrate emulsion for assay of lipoprotein lipase","volume":"17","author":"Nilsson-Ehle","year":"1976","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2024.12.018_bib0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clinbiochem.2023.02.002","article-title":"Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity","volume":"114","author":"Brisson","year":"2023","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jacl.2024.12.018_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacl.2020.01.014","article-title":"Chylomicronemia syndrome: familial or not?","volume":"14","author":"Warden","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.12.018_bib0026","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2024.12.018_bib0027","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742400299X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742400299X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T02:11:49Z","timestamp":1750903909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742400299X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S193328742400299X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.12.018","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}